Login to Your Account

Takeda Pays $6M Up Front

Archemix Nails Down Two Deals; $29.8M From Merck

By Randall Osborne

Tuesday, June 12, 2007
Aptamer-focused Archemix Inc. added to a deal spree that tapered at the start of the year, and found two nice fits overseas, including a cancer pact worth $29.8 million in up-front equity from Merck KGaA, plus an option to buy more stock when the firm goes public.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription